Thyroid cancer treatment with targeted therapy

Targeted thyroid therapy is prescribed to patients with inoperable thyroid cancer, which has proven resistant to radioiodine therapy and progresses within 3-12 months. Targeted drugs disable the ability of cancer cells to grow and spread. They focus on the changes characteristic of cancer cells rather than attacking all rapidly dividing cells in a row, like chemotherapy drugs. The treatment program begins with molecular genetic tests for studying thyroid cancer cells and determining the factor that caused their growth. Next, the oncologist identifies the genetic mutations that caused the tumor and determines the sensitivity of cancer to certain medications. Then a drug is selected that helps the body find, recognize and kill cancer cells. The most important thing is that these drugs affect only malignant cells without causing any damage to healthy ones. Targeted drugs are administered using droppers with a specific frequency (for example, once every 21 days or once every 14 days). The introduction of the drug takes little time. As a rule, it lasts up to 2 hours. The thyroid cancer treatment with targeted medications is well tolerated by patients and has minimal side effects.